Table 2. Summary of text linked to residue mentions for a random sample of high-quality predictions.
PDB ID (Chain) | Protein Name | Residue(s) | Text summary |
153L (A) | Goose lysozyme | Glu73a | NAG O6 directly hydrogen bonds to Glu73 OE2 [59] |
1AB0 (A) | V32D/F57H Adipocyte Lipid-Binding Protein | Asp32, His57, and Cys117b | Phe57 in WT is part of the ligand binding portal, and Asp32 and His57 form a salt bridge in the mutant that controls access to the ligand binding site. Cys117 lies within the internal lipid-binding cavity [60] |
1EYJ (A) | Fructose 1,6-Biphosphatase | Asp74b | Asp74 is involved in the forward reaction of this enzyme [61] |
1GU9 (A) | Mtb alkhydro-peroxidase | Cys133, His137 | Cys133 is a catalytic sulfhydryl group,His137 is involved in a relay to deprotonate Cys133 [62] |
1I8B (B) | Chalcone synthase | Phe256a | Gly256 is in the active site in the wild type and the whole paper is about mutations to this residue, including G256F [63] |
1LAR (A) | Receptor-like protein tyrosine phosphatase LAR | Leu1644 | Leu1644 is responsible for inactivity of the protein and mutation to Tyr conferred robust PTPase activity to D2 domain [64] |
1QOB (A) | Anabaena ferrodoxin | Gln70 | Gln70 is at an interface that makes contact with a key interface but is not as critical as other residues in determining oxidation kinetics [65] |
1TS2 (A) | Toxic shock syndrome toxin-1 | His135, Gln136 | H135A appears to reduce superantigenicity by altering properties of TCR interaction surface and is tied for the largest joint reduction in superantigenicity and lethality. Q136A causes a dramatic conformational change [66] |
1XYH (A) | Human cyclophilin J | Gln52b | Gln52 expected to be an active site based on sequence alignment [67] |
1YK3 (A) | Putative antibiotic resistance protein from Mtb | His130, Asp168b | His130 and Asp168 are both in the active site and have a putative roles in substrate binding and catalysis [40] |
Family-level NSM annotation available.
Family-level NSM-valid annotation available.